Kalaris Therapeutics KLRS Institutional Ownership

Kalaris Therapeutics, Inc. (NASDAQ:KLRS) has 57 institutional investors with active 13F positions as of June 2026.

• Their combined ownership stood at 75.8% of outstanding shares in June 2026, down from 78.3% in March 2026.
• They increased total shares held in Kalaris Therapeutics by 4.71% from the prior quarter, while the number of investors in KLRS increased 90.0% year over year.
• Activity in KLRS broke down as 28 buyers, 9 sellers, and 20 unchanged among 57 total holders.
• In total, institutional investors held 18.04Mn shares in Kalaris Therapeutics as of June 2026, up by 810.48K shares quarter on quarter, and up 4.68Mn shares year over year.
• As of June 30, 2026, the biggest holder of Kalaris Therapeutics is Samsara BioCapital, LLC at 12.88Mn shares, representing 54.13% of shares outstanding.
• Top purchasers of KLRS stock for the quarter ending June 2026 included UBS Group AG (255.95K), VANGUARD CAPITAL MANAGEMENT LLC (143.36K), CITADEL ADVISORS LLC (95.77K), RENAISSANCE TECHNOLOGIES LLC (83.2K), Verdad Advisers, LP (80.3K).
• The largest sellers of Kalaris Therapeutics for the quarter ending June 2026 were Goldman Sachs Group Inc (94.45K), Samsara BioCapital, LLC (66.91K), SUSQUEHANNA INTERNATIONAL GROUP, LLP (38.46K), Raymond James Financial Inc (21.72K), TWO SIGMA INVESTMENTS, LP (6.8K).
• Business Quant data shows the 10 biggest positions in Kalaris Therapeutics as of June 2026 are held by Samsara BioCapital, LLC (12.88Mn), RTW INVESTMENTS, LP (1.3Mn), Alyeska Investment Group, L.P. (572.69K), Siren, L.L.C. (435.8K), VANGUARD CAPITAL MANAGEMENT LLC (398.71K), Ikarian Capital, LLC (360.0K), UBS Group AG (262.13K), RENAISSANCE TECHNOLOGIES LLC (149.35K), MARSHALL WACE, LLP (139.2K), GEODE CAPITAL MANAGEMENT, LLC (114.04K).